TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $856,719 | -54.6% | 95,830 | -22.0% | 0.00% | -100.0% |
| Q2 2023 | $1,887,683 | +19.3% | 122,896 | +74.6% | 0.00% | – |
| Q1 2023 | $1,582,801 | +2233.8% | 70,378 | +2082.3% | 0.00% | – |
| Q4 2022 | $67,822 | -48.2% | 3,225 | -39.7% | 0.00% | – |
| Q3 2022 | $131,000 | +27.2% | 5,348 | +25.4% | 0.00% | – |
| Q2 2022 | $103,000 | -90.6% | 4,265 | -90.0% | 0.00% | – |
| Q1 2022 | $1,096,000 | -41.6% | 42,530 | -29.6% | 0.00% | – |
| Q4 2021 | $1,876,000 | +67.8% | 60,425 | +31.1% | 0.00% | – |
| Q3 2021 | $1,118,000 | -63.6% | 46,106 | -78.1% | 0.00% | -100.0% |
| Q2 2021 | $3,073,000 | -18.6% | 210,626 | +39.4% | 0.00% | 0.0% |
| Q1 2021 | $3,774,000 | +23.5% | 151,108 | +34.7% | 0.00% | 0.0% |
| Q4 2020 | $3,056,000 | – | 112,147 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |